Pinz Capital Management’s Atossa Therapeutics ATOS Stock Holding History

Pinz Capital Management’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,193	Closed	-$20K	–	108
2022 Q2	$20K	Buy	+1,193	New	+$18.8K	0.01%	213

Other funds holding ATOS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Pinz Capital Management's ATOS Position: Q3 2022 in Review

Pinz Capital Management sold out of Atossa Therapeutics (ATOS) in Q3 2022, closing a stake of 1,193 shares — an estimated $20K sold.

Pinz Capital Management first reported a position in ATOS in Q2 2022 and held it in 1 quarter. The position peaked at $20K in Q2 2022. 56 funds tracked by Wall St. Rank hold ATOS as of Q3 2022.

Pinz Capital Management reported no remaining Atossa Therapeutics position as of Q3 2022 after selling out during the quarter.
Pinz Capital Management sold 1,193 Atossa Therapeutics shares in Q3 2022, an estimated $20K.
Pinz Capital Management first reported a position in Atossa Therapeutics in Q2 2022 and held it in 1 quarter.
Pinz Capital Management's Atossa Therapeutics position peaked at $20K in Q2 2022.
56 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q3 2022.

Based on Pinz Capital Management's 13F filing for Q3 2022, filed 15 Nov 2022.